Emerging Opportunities in Duchenne Muscular Dystrophy (DMD) Market with Current Trends Analysis (2017-2025)

Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by muscle degeneration and weakness. Duchenne muscular dystrophy (DMD) cause due to lack of protein known as “dystrophin” which causes muscles deterioration and break down, leads to difficulty in walking and general mobility. DMD is a one of the most progressive childhood neuromuscular disorders. It affects mostly boys, but occasionally girls are affected. According to Muscular Dystrophy Australia, in 2016, Duchenne muscular dystrophy affected approximately 1 in 3500 male births across the world. Symptoms of Duchenne muscular dystrophy are frequent falls, muscle pain and stiffness, trouble running and jumping, and difficulty getting up from a lying or sitting position, among others. DMD can be caused due to cardiac, neuromuscular, and orthopedic disorders.

Report Overview and TOC @ https://www.transparencymarketresearch.com/duchenne-muscular-dystrophy-market.html

Increasing research and development, introduction of novel disease therapies, rising demand for effective therapies among patients, and increasing disease prevalence are projected to fuel the growth of the global Duchenne muscular dystrophy market. According to the Centers for Disease Control and Prevention, in 2016, prevalence of Duchenne and Becker muscular dystrophy (DBMD) was 1 in every 7,250 males aged 5 to 24 years. Rising prevalence of chronic diseases such as cardiovascular, neurovascular, and arthritis, and increasing health care insurance coverage are the other factors likely to accelerate the growth of the global Duchenne muscular dystrophy market. According to the World Health Organization, cardiovascular diseases accounted for 17.7 million deaths in 2015, representing 31% of all global deaths. However, stricter regulation for product approvals and high product cost are likely to restrain the Duchenne muscular dystrophy market.

Request for Broucher @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28145

The Duchenne muscular dystrophy (DMD) market has been segmented based on treatment type, diagnosis, end-user, and region. In terms of treatment type, the market has been classified into drug therapy and novel therapy. The drug therapy segment has been sub-segmented into corticosteroids and others. The novel therapy segment has been categorized into gene therapy, stem cell therapy, utrophin, and others. In terms of diagnosis, the Duchenne muscular dystrophy market has been classified into blood tests, gene tests, and muscle biopsy. Based on end-user, the market has been classified into hospitals, specialty clinics, and ambulatory surgery centers.

For Specific and Customized Requirements @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=28145

Geographically, the Duchenne muscular dystrophy market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global Duchenne muscular dystrophy market due to new product innovation, high health care expenditure, and government awareness programs. The United Parent Projects Muscular Dystrophy initiated World Duchenne Awareness Day. The aim of Duchenne Awareness Day is to raise awareness about Duchenne muscular dystrophy across the globe and September 7 has been declared as Duchenne Awareness Day. Europe is the second largest market for Duchenne muscular dystrophy. The market in Asia Pacific is expected to grow at higher rate due to rapid rise in population, growing prevalence of chronic diseases, increasing health care coverage, and rising investment in research and development. Emerging regions such as Latin America and Middle East & Africa will create a large opportunity in the global Duchenne muscular dystrophy market due to growing awareness among people, increasing public and private health care insurance coverage, etc.

Pre Book Full Report @ https://www.transparencymarketresearch.com/duchenne-muscular-dystrophy-market.html?secure=NTIxNS41&type=PB

Major players operating in the global Duchenne muscular dystrophy market include Pfizer, Inc., Eli Lilly and Company, Nobelpharma Co., Ltd., Sarepta Therapeutics, Inc., Tivorsan Pharmaceuticals, Acceleron Pharma, Inc., BioMarin Pharmaceutical, Inc., Asklepios Kliniken GmbH, FibroGen, Inc., and Santhera Pharmaceuticals Holding.

ABOUT US:
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

CONTACT:
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-345

This release was published on openPR.